Jensen v. Life Insurance Company of North America

CourtDistrict Court, D. Utah
DecidedJanuary 4, 2024
Docket2:22-cv-00293
StatusUnknown

This text of Jensen v. Life Insurance Company of North America (Jensen v. Life Insurance Company of North America) is published on Counsel Stack Legal Research, covering District Court, D. Utah primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Jensen v. Life Insurance Company of North America, (D. Utah 2024).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF UTAH

JILL L. JENSEN,

Plaintiff, MEMORANDUM DECISION AND ORDER vs. Case No. 2:22-CV-293-DAK-DAO LIFE INSURANCE COMPANY OF NORTH AMERICA, et al., Judge Dale A. Kimball

Defendants. Magistrate Judge Daphne A. Oberg

This matter is before the court on Plaintiffs Jill L. Jensen’s Motion for Summary Judgment [ECF No. 20]. On October 31, 2023, the court held a hearing on the motion. At the hearing, Brian S. King represented Plaintiff, and James L. Barnett represented Defendant Life Insurance Company of North America. The court took the motion under advisement. After carefully considering the memoranda filed by the parties and the law and facts relevant to the pending motion, the court issues the following Memorandum Decision and Order. BACKGROUND Plaintiff Jill L. Jensen’s (“Jensen”) husband Steven D. Jensen (‘Steven”), died on February 1, 2019. At the time of his death, Steven was employed at Codale Electric Supply, Inc.(“Codale”). Codale established a group employee benefit welfare plan (“Plan”) for eligible employees and their dependents, which is governed by the Employee Retirement Income Security Act, 29 U.S.C. §§ 1001-1461 (“ERISA”). The Plan provides Accidental Death & Dismemberment (“AD&D”) benefits funded by a Group Accident Policy through Defendant Life Insurance Company of North America (“LINA”). The Group Accident Policy has an effective date of July 1, 2010, and is ERISA.” Codale, as the Plan Administrator, appointed LINA as a Claim Fiduciary “responsible for adjudicating claims for benefits under the Plan.” LINA is both the claim administrator for

AD&D claims and the entity responsible for the funding of the Plan’s AD&D benefits. Jensen also sued Cigna Health and Life Insurance Company but dismissed it as a defendant early in the case. Steven had been suffering from chronic pain for many years and had a prescription for oxycodone for over five years before his death. Steven received treatment from Andrew Ward at a pain management clinic, who renewed Steven’s prescription six weeks before he died. Ward conducted a psychiatric assessment among other screening evaluations and determined that Steven was using his oxycodone properly. On January 30, 2019, Steven saw Dr. Michael Cosgrave, who prescribed Steven clonazepam to take as needed to manage his anxiety. Dr. Cosgrave did not indicate that Steven had

any psychiatric risk of suicide or suicidal ideation. On the night of January 31, 2019, Steven went to bed, and on February 1, 2019, Jensen found Steven dead in the bedroom. Steven’s autopsy determined that he died of “oxycodone and clonazepam toxicity” and noted that the manner of death was an accident. The potential for death when mixing oxycodone and clonazepam is documented in medical literature. On September 4, 2019, Jensen’s attorney wrote to LINA, explaining that Jensen had submitted claims to LINA for Steven’s accidental death that LINA had not acknowledged, demanding that LINA pay the life insurance and AD& D benefits available under Steven’s benefits plan with Codale within thirty days, and including Steven’s death certificate. LINA responded in a letter, dated September 12, 2019, stating that LINA was contacting the policyholder

for additional information and that while the review was ongoing, LINA would provide a status update every thirty days. On October 1, 2019, LINA approved the life insurance claim. In a separate letter, also dated October 1, 2019, LINA stated that the accidental death claim was still being reviewed and

that it would provide updates every thirty days. The letter also asked Jensen to sign and return a records request authorization form. On October 15, 2019, Jensen’s attorney submitted the form. On December 4, 2019, LINA denied the AD&D claim because it did not satisfy all the applicable policy provisions. The cover page of the Policy states that “THIS IS A GROUP ACCIDENT ONLY INSURANCE POLICY. IT DOES NOT PAY BENEFITS FOR LOSS CAUSED BY SICKNESS.” The Policy defines a “Covered Accident” as “[a] sudden, unforeseeable, external event that results, directly and independently of all other causes, in a Covered Injury or Covered Loss and meets all of the following conditions: . . . 2. Is not contributed to by disease, Sickness, mental or bodily infirmity; 3. Is not otherwise excluded under the terms of

the Policy.” The Policy excluded from coverage any injury or loss “which, directly or indirectly, in whole or in part, is caused by or results from . . . . 7. Sickness, disease, bodily or mental infirmity, bacterial or medical or surgical treatment thereof, . . . . [or] 11. Voluntary ingestion of any narcotic, drug, poison, gas or fumes, unless prescribed or taken under the direction of a Physician and taken in accordance with the prescribed dosage.” LINA’s letter explained that “the Assistant Medical Examiner specifically states that Mr. Jensen had ‘a high toxic/borderline lethal level of oxycodone’ in his blood, and the level of this drug found in his system is within the documented lethal range. Thus, the levels of these drugs are higher than would be expected . . . if taken as prescribed..” LINA also noted that the autopsy diagnosis of pulmonary edema was “consistent with drug overdose and abuse,” the “pill count

showed that [Steven] was ‘short 73 oxycodone,’ and Steven “was believed to have previously overdosed on oxycodone.” Based on these findings, LINA concluded that Steven’s death was “’directly or indirectly, in whole or in part,’ caused by or the result of his ‘voluntary ingestion of any narcotic, drug’ namely, oxycodone, that he was not taking ‘in accordance with the prescribed

dosage.” LINA also denied the claim based on the policy’s exclusion for any injury or loss caused by or the result of sickness, disease, bodily or mental infirmity because Steven was prescribed the medications for chronic conditions, not to treat any accidental injury or trauma. Jensen appealed LINA’s denial and included the autopsy report from the Utah Office of Medical Examiner which stated the manner of death was an accident and that the immediate cause of death was oxycodone and clonazepam toxicity. Jensen argued that the toxicology results do not show that Steven overdosed or took any amount of oxycodone beyond the prescribed amount. Jensen also retained Dr. Randall Baselt, who reviewed the relevant documents and concluded that the concentrations of the drugs were consistent with what he would expect to find in someone

taking oxycodone and clonazepam as they were prescribed to Steven. In a letter, dated January 24, 2020, Dr. Baselt confirmed that based on his review, Steven was taking the drugs consistent with how they were prescribed to him. Jensen also included in the appeal two dozen letters from family and friends stating that Steven was a happy person who would not commit suicide. After two extensions to review the appeal, on April 28, 2020, LINA upheld the denial of the AD&D claim. LINA noted that Dr. Baselt had opined that Steven was taking oxycodone and clonazepam consistent with how they were prescribed. LINA’s denial letter further stated that all the information in the claim file was sent to Dr. Richard T. Tovar, who is Board Certified in Medical Toxicology. Dr. Tovar opined that “there is no medical toxicology evidence of any inappropriate usage of oxycodone prior to the decedent’s demise. Furthermore, it is not medically

possible to determine from a post mortem drug confirmatory blood test if the decedent was taking his medication in an appropriate fashion. All that can be stated is that the decedent died of mix drug toxicity from Oxycodone, Clonazepam, and Escitalopram.” Therefore, LINA did not affirm denial of the claim based on the inappropriate usage of medication.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Metropolitan Life Insurance v. Glenn
554 U.S. 105 (Supreme Court, 2008)
Hancock v. Metropolitan Life Insurance
590 F.3d 1141 (Tenth Circuit, 2009)
McClenahan v. Metropolitan Life Insurance Co
416 F. App'x 693 (Tenth Circuit, 2011)
Grobe v. Vantage Credit Union
679 F. Supp. 2d 1020 (E.D. Missouri, 2010)
Harvey v. Cedar Hills City
2010 UT 12 (Utah Supreme Court, 2010)
Davis v. Fed. Ins. Co.
382 F. Supp. 3d 1189 (W.D. Oklahoma, 2019)
Raymond v. Life Insurance Co. of North America
924 F. Supp. 2d 1345 (S.D. Florida, 2010)
Cady v. Hartford Life & Accidental Insurance
930 F. Supp. 2d 1216 (D. Idaho, 2013)

Cite This Page — Counsel Stack

Bluebook (online)
Jensen v. Life Insurance Company of North America, Counsel Stack Legal Research, https://law.counselstack.com/opinion/jensen-v-life-insurance-company-of-north-america-utd-2024.